IlluminOss Medical, Inc.

The safety and performance pathway and de novo clearance process are combining to reform the US Food and Drug Administration’s approach to device approvals, agency officials said on 14 September at RA

Company Changes AVILA , Manny To: IlluminOss Medical Inc. , CEO (October) From: OmniGuide Inc., Global VP, Sales & Mktg. Phone: 401-714-0008 CLENDENINN , Neil J., MD, PhD To: Heron Therapeu

New At The Helm Company Changes ALMEIDA , Joe To: Baxter International Inc. , Chmn. & CEO (Jan. 2016) From: Covidien PLC, Pres. & CEO Phone: 847-948-2000 AVILA , Manny To: IlluminOss Medica

Company Changes AGRAWAL , Amit To: Bellerophon Therapeutics Inc. , COO (July) From: Amgen Inc., Dir., Strategy & Corp. Dev. Phone: 908-574-4770 ARMOUR , Alison A., MD To: Endocyte Inc. , C